A Phase 3 interventional study of Ertugliflozin 5 mg and Ertugliflozin 10 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-29.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 8th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Amsterdam UMC, location VUmc · Sites in United States, Netherlands
Ages 18–85
Baylor Research Institute · Sites in United States
Ages 18–84
Shanghai Zhongshan Hospital · Sites in China
Ages 19+
By country, each count listing its studies:
ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 461 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 83 across the 28 interventional studies. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 52nd largest by enrollment of the 170 interventional ones that give a count, is one of 13 that started in 2013, is one of 86 in phase 3, and was the 151st registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial will evaluate the efficacy and safety of ertugliflozin monotherapy in the treatment of participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on diet and exercise. This trial consists of a run-in period of 3 to 11 weeks, a 26-week placebo-controlled treatment period (Phase A), and a 26-week active treatment period (Phase B). The primary hypotheses of the trial are that at Week 26, the mean reduction from baseline in hemoglobin A1c (A1C) for 15 mg ertugliflozin is greater than that for placebo and the mean reduction from baseline in A1C for 5 mg ertugliflozin is greater than that for placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
Drug: Ertugliflozin 5 mg · Drug: Placebo to Ertugliflozin · Drug: Metformin · Drug: Placebo to Metformin · Drug: Glimepiride
Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
Drug: Ertugliflozin 5 mg · Drug: Ertugliflozin 10 mg · Drug: Metformin · Drug: Placebo to Metformin · Drug: Glimepiride
Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
Drug: Placebo to Ertugliflozin · Drug: Metformin · Drug: Glimepiride
One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
Also known as: MK-8835, PF-04971729
One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
Also known as: MK-8835, PF-04971729
One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.
Also known as: Glucophage XR, Carbophage SR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, Diaformin, Siofor and Metfogamma.
1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.
Dosing and titration of glimepiride as rescue therapy was determined by the investigator.
Change From Baseline In A1C at Week 26
A1C is measured as percent. The change from baseline is the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 26
Percentage of Participants Experiencing An Adverse Event (AE)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.
Time frame: Up to 54 weeks (including 2 weeks following last dose)
Percentage of Participants Discontinuing Study Treatment Due to an AE
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.
Time frame: Up to 52 weeks
Change From Baseline in FPG at Week 26
The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in Body Weight at Week 26
The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 26
Percentage of Participants With A1C <7% (<53 mmol/Mol) at Week 26
A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
Time frame: Week 26
Baseline 2-hour Post-prandial Glucose (2-hr PPG) Level
Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the Mixed Meal Tolerance Test (MMTT). Change from baseline in 2-hr PPG level at Week 26 data are presented in the following outcome measure.
Time frame: Baseline
Change From Baseline in 2-hr PPG at Week 26
The change from baseline is the Week 26 2-hr PPG minus the Week 0 2-hr PPG. Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the MMTT. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 26
Baseline Sitting Systolic Blood Pressure (SBP)
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in SBP at Week 26 data are presented in the following outcome measure.
Time frame: Baseline
Change From Baseline in SBP at Week 26
The change from baseline is the Week 26 SBP minus the Week 0 SBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 26
Baseline Sitting Diastolic Blood Pressure (DBP)
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in DBP at Week 26 data are presented in the following outcome measure.
Time frame: Baseline
Change From Baseline in DBP at Week 26
The change from baseline is the Week 26 DBP minus the Week 0 DBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.
Time frame: Baseline and Week 26
| Milestone | Ertugliflozin 5 mg/Ertugliflozin 5 mg | Ertugliflozin 15 mg/Ertugliflozin 15 mg | Placebo/Metformin |
|---|---|---|---|
| Started | 156 | 152 | 153 |
| Completed | 137 | 128 | 121 |
| Not completed | 19 | 24 | 32 |
| Withdrew: Adverse event | 1 | 1 | 5 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Excluded medication | 0 | 0 | 1 |
| Withdrew: Hyperglycemia | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 7 | 11 | 7 |
| Withdrew: Non-compliance with study drug | 1 | 1 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Study site terminated by sponsor | 1 | 0 | 1 |
| Withdrew: Participant moved | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 8 | 10 | 13 |
A1C is measured as percent. The change from baseline is the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
| Percent | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline In A1C at Week 26 | -0.79 (-0.95 to -0.63) | -0.96 (-1.12 to -0.80) | 0.20 (0.02 to 0.37) |
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.
| Percentage of participants | Ertugliflozin 5 mg/Ertugliflozin 5 mg | Ertugliflozin 15 mg/Ertugliflozin 15 mg | Placebo/Metformin |
|---|---|---|---|
| Percentage of Participants Experiencing An Adverse Event (AE) | 64.1 | 62.5 | 66.7 |
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.
| Percentage of participants | Ertugliflozin 5 mg/Ertugliflozin 5 mg | Ertugliflozin 15 mg/Ertugliflozin 15 mg | Placebo/Metformin |
|---|---|---|---|
| Percentage of Participants Discontinuing Study Treatment Due to an AE | 4.5 | 3.9 | 6.5 |
The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of glycemic rescue therapy.
| mg/dL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in FPG at Week 26 | -33.96 (-39.85 to -28.06) | -43.44 (-49.39 to -37.49) | 0.57 (-6.02 to 7.16) |
The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.
| Kilograms | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 26 | -3.18 (-3.72 to -2.63) | -3.58 (-4.13 to -3.02) | -1.42 (-2.02 to -0.81) |
A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With A1C <7% (<53 mmol/Mol) at Week 26 | 28.2 | 35.8 | 13.1 |
Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the Mixed Meal Tolerance Test (MMTT). Change from baseline in 2-hr PPG level at Week 26 data are presented in the following outcome measure.
| mg/dL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Baseline 2-hour Post-prandial Glucose (2-hr PPG) Level | 260.32 ± 76.110 | 262.91 ± 78.189 | 256.21 ± 76.917 |
The change from baseline is the Week 26 2-hr PPG minus the Week 0 2-hr PPG. Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the MMTT. Data presented exclude data following the initiation of rescue therapy.
| mg/dL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in 2-hr PPG at Week 26 | -64.15 (-74.34 to -53.96) | -62.45 (-72.91 to -51.98) | 4.88 (-6.15 to 15.92) |
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in SBP at Week 26 data are presented in the following outcome measure.
| mmHg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Baseline Sitting Systolic Blood Pressure (SBP) | 130.49 ± 13.511 | 129.67 ± 14.208 | 129.80 ± 14.464 |
The change from baseline is the Week 26 SBP minus the Week 0 SBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.
| mmHg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in SBP at Week 26 | -5.54 (-7.32 to -3.76) | -3.93 (-5.74 to -2.12) | -2.22 (-4.30 to -0.14) |
Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in DBP at Week 26 data are presented in the following outcome measure.
| mmHg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Baseline Sitting Diastolic Blood Pressure (DBP) | 78.46 ± 8.117 | 78.53 ± 7.714 | 78.13 ± 7.458 |
The change from baseline is the Week 26 DBP minus the Week 0 DBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.
| mmHg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in DBP at Week 26 | -2.52 (-3.65 to -1.40) | -1.10 (-2.24 to 0.05) | -0.72 (-2.05 to 0.60) |
Collected over Up to 54 weeks (+/- 3 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ertugliflozin 5 mg/Ertugliflozin 5 mg | — | 11/156 (7.1%) | 50/156 (32.1%) |
| Ertugliflozin 15 mg/Ertugliflozin 15 mg | — | 6/152 (3.9%) | 48/152 (31.6%) |
| Placebo/Metformin | — | 8/153 (5.2%) | 68/153 (44.4%) |
| Event | Ertugliflozin 5 mg/Ertugliflozin 5 mg | Ertugliflozin 15 mg/Ertugliflozin 15 mg | Placebo/Metformin |
|---|---|---|---|
| LabyrinthitisInfections and infestations | 0/156 | 1/152 | 0/153 |
| Periorbital abscessInfections and infestations | 0/156 | 1/152 | 0/153 |
| Periorbital cellulitisInfections and infestations | 0/156 | 1/152 | 0/153 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/156 | 1/152 | 0/153 |
| Hepatic cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/156 | 1/152 | 0/153 |
| Squamous cell carcinoma of lungNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/156 | 1/152 | 0/153 |
| Squamous cell carcinoma of the cervixNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/156 | 1/152 | 0/153 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/156 | 1/152 | 0/153 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/156 | 1/152 | 0/153 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/156 | 1/152 | 0/153 |
| Event | Ertugliflozin 5 mg/Ertugliflozin 5 mg | Ertugliflozin 15 mg/Ertugliflozin 15 mg | Placebo/Metformin |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 8/156 | 5/152 | 23/153 |
| Urinary tract infectionInfections and infestations | 13/156 | 10/152 | 19/153 |
| NauseaGastrointestinal disorders | 4/156 | 3/152 | 12/153 |
| Vulvovaginal mycotic infectionInfections and infestations | 12/156 | 8/152 | 2/153 |
| NasopharyngitisInfections and infestations | 8/156 | 11/152 | 6/153 |
| ConstipationGastrointestinal disorders | 11/156 | 2/152 | 4/153 |
| Upper respiratory tract infectionInfections and infestations | 9/156 | 10/152 | 9/153 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/156 | 6/152 | 10/153 |
| HeadacheNervous system disorders | 6/156 | 7/152 | 9/153 |
| BronchitisInfections and infestations | 5/156 | 1/152 | 8/153 |
| Age, Continuous(Years) | Ertugliflozin 5 mg/Ertugliflozin 5 mg | Ertugliflozin 15 mg/Ertugliflozin 15 mg | Placebo/Metformin | Total |
|---|---|---|---|---|
| Mean | 56.8 ± 11.4 | 56.2 ± 10.8 | 56.1 ± 10.9 | 56.4 ± 11.0 |
| Sex: Female, Male(Participants) | Ertugliflozin 5 mg/Ertugliflozin 5 mg | Ertugliflozin 15 mg/Ertugliflozin 15 mg | Placebo/Metformin | Total |
|---|---|---|---|---|
| Female | 67 | 62 | 71 | 200 |
| Male | 89 | 90 | 82 | 261 |
| Hemoglobin A1c (A1C)(Percent) | Ertugliflozin 5 mg/Ertugliflozin 5 mg | Ertugliflozin 15 mg/Ertugliflozin 15 mg | Placebo/Metformin | Total |
|---|---|---|---|---|
| Mean | 8.16 ± 0.88 | 8.35 ± 1.12 | 8.11 ± 0.92 | 8.21 ± 0.98 |
| Fasting plasma glucose (FPG)(mg/dL) | Ertugliflozin 5 mg/Ertugliflozin 5 mg | Ertugliflozin 15 mg/Ertugliflozin 15 mg | Placebo/Metformin | Total |
|---|---|---|---|---|
| Mean | 180.9 ± 48.5 | 179.1 ± 48.2 | 180.2 ± 45.8 | 180.1 ± 47.4 |
| Estimated glomerular filtration rate (eGFR)(mL/min/1.75m^2) | Ertugliflozin 5 mg/Ertugliflozin 5 mg | Ertugliflozin 15 mg/Ertugliflozin 15 mg | Placebo/Metformin | Total |
|---|---|---|---|---|
| Mean | 88.5 ± 18.4 | 88.3 ± 18.0 | 86.2 ± 19.4 | 87.7 ± 18.6 |
| Body weight(Kilograms) | Ertugliflozin 5 mg/Ertugliflozin 5 mg | Ertugliflozin 15 mg/Ertugliflozin 15 mg | Placebo/Metformin | Total |
|---|---|---|---|---|
| Mean | 94.0 ± 25.4 | 90.6 ± 18.3 | 94.2 ± 25.2 | 92.9 ± 23.2 |
No study locations are listed for this record.
Ran from Oct 2013 to primary completion in Jul 2016, 33 months.
Results were first posted in Sep 2017, 1 year 2 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 33 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertugliflozin